Odyssey Therapeutics, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
FMR LLC and Abigail P. Johnson have reported a 10.2% beneficial ownership stake in Odyssey Therapeutics Inc. common stock.
NASDAQ
Lightspeed Venture Partners XV-B (Ignite), L.P. has filed a Schedule 13G reporting a 7.6% beneficial ownership stake in Odyssey Therapeutics, Inc.